Publication
HER2 activating mutations are targets for colorectal cancer treatment.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (12)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 12
- cancerMalignant Colon Neoplasmcivic_curation1.00
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugCetuximabcivic_curation1.00
- drugLapatinibcivic_curation1.00
- drugNeratinibcivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 L755Scivic_curation1.00
- variantERBB2 L866Mcivic_curation1.00
- variantERBB2 S310F/Ycivic_curation1.00
- variantERBB2 V777Lcivic_curation1.00
- variantERBB2 V842Icivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26243863
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 L755S2 | ||||||||
| Lapatinib + Neratinib + TrastuzumabCombination | Malignant Colon Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID1176Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID4519In an in vitro study, NCI-H508 cell lines expressing an ERBB2 L755S mutation demonstrated resistance to cetuximab treatment (IC50 > 200 ug/mL) compared with NCI-H508 cells expressing ERBB2 wild type (… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| ERBB2 L866M2 | ||||||||
| Lapatinib + Neratinib + TrastuzumabCombination | Malignant Colon Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID1178Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | — | submitted | EID4673bp] In an in vitro study, NCI-H508 cell lines expressing an ERBB2 L866M mutation demonstrated resistance to cetuximab treatment compared to NCI-H508 cells expressing ERBB2 wild-type. Resistance was de… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| ERBB2 S310F/Y2 | ||||||||
| Lapatinib + Neratinib + TrastuzumabCombination | Malignant Colon Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID1179Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | — | submitted | EID4518bp]In an in vitro study, NCI-H508 cell lines expressing an ERBB2 S310F mutation demonstrated resistance to cetuximab treatment, compared to NCI-H508 cells expressing ERBB2 wild-type. Resistance was de… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| ERBB2 V777L2 | ||||||||
| Lapatinib + Neratinib + TrastuzumabCombination | Malignant Colon Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID1177Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID4452In an in vitro study, NCI-H508 cell lines expressing an ERBB2 V777L mutation demonstrated resistance to cetuximab treatment (IC50 >200 ug/ml) compared to NCI-H508 cells expressing ERBB2 wild-type (IC5… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| ERBB2 V842I2 | ||||||||
| Lapatinib + Neratinib + TrastuzumabCombination | Malignant Colon Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID1174Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | — | submitted | EID4520bp]In an in vitro study, DiFi and NCI-H508 cell lines expressing an ERBB2 V842I mutation demonstrated resistance to cetuximab treatment, compared to DiFi and NCI-H508 cells expressing ERBB2 wild-type.… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC | civic |